Drug Profile

Research programme: visceral leishmaniasis therapeutics - Advinus Therapeutics/DNDi/Global Alliance for TB Drug Development

Alternative Names: DNDI-8219; VL-2098

Latest Information Update: 02 Aug 2019

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Global Alliance for TB Drug Development
Developer Advinus Therapeutics; Drugs for Neglected Diseases Initiative Foundation
Class Nitroimidazoles
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

02 Aug 2019 Discontinued - Preclinical for Visceral leishmaniasis in India (PO)
02 Aug 2019 Discontinued - Preclinical for Visceral leishmaniasis in Switzerland (PO)
04 Nov 2017 No recent reports of development identified for preclinical development in Visceral-leishmaniasis in India (PO)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com